

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

June 2019



The Vertical Portal for China Business Intelligence

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- To establish a comprehensive, factual, annually updated and costeffective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Copyright 2012 ResearchInChina

The Vertical Portal for China Business Intelligence

Abstract

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China's IVD market has burgeoned due to robust demand over the years, with its size approximating RMB57.6 billion in 2018, an annualized jump of 19.3%.

Reagents now prevail in the Chinese IVD industry, sweeping over 70% of the total value of the industry. In the country, IVD reagents mainly include those for immunological, biochemical and molecular diagnostics, among which the first two kinds of diagnosis reagents are the mainstay of the industry, seizing a combined more than 60% shares.

In China, world-renowned big names such as Roche, Siemens, Abbott and Thermo Fisher are the main players in the high-end IVD market; local companies including Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shanghai Kehua Bio-Engineering Co., Ltd., Maccura Biotechnology Co., Ltd., Autobio Diagnostics Co., Ltd., Dirui Industrial Co., Ltd., Beijing Leadman Biochemistry Co., Ltd., MedicalSystem Biotechnology Co., Ltd. and Sinocare Inc., have gained a firm foothold in the low- and mid-end markets.

China has issued industrial policies to shore up local Chinese IVD companies since 2011, setting the stage for homemade products to replace the imported. Lower price and favorable policies are a boon for Chinese companies to break the monopoly of their foreign peers.

China's IVD industry will head toward the following directions in the years to come:


- 1. Factors such as population aging, two-child policy and higher health budget will be conducive to the rising demand for IVD;
- 2. Frequent mergers and acquisitions will make the market more concentrated;
- 3. High-end immunological diagnostics, molecular diagnostics and point-of-care testing (POCT) will be three major trends.

The report highlights the following:

- China IVD industry (development status, market size, market structure, competitive pattern and development trends);
- China IVD market segments (development status, competitive pattern and development trends);
- China IVD downstream sectors;
- 6 foreign and 24 Chinese IVD companies (operation, gross margin, IVD business, development strategy, etc.).

Copyright 2012ResearchInChina

The Vertical Portal for China Business Intelligence



Copyright 2012ResearchInChina

The Vertical Portal for China Business Intelligence

Table of contents

1 Overview

- 1.1 Definition
- 1.2 Classification

2 China In Vitro Diagnostic Industry

- 2.1 Development Status
- 2.2 Market Size
- 2.3 Market Structure
- 2.4 Competitive Pattern
- 2.5 Development Trends
- 2.5.1 Aging of Population Spurs IVD Industry
- 2.5.2 Higher Healthcare Expenditures are a Boon for IVD Industry
- 2.5.3 Government Backs IVD Industry
- 2.5.4 High-end Immunological Diagnostics, Molecular Diagnostics and POCT will be Three Major Trends
- 2.5.5 Related Companies Flock to Capital Market for Further Development
- 2.5.6 Implementation of Two-child Policy Fuels IVD Industry
- 2.5.7 Frequent Mergers and Acquisitions are Likely to Make IVD Market More Concentrated

3 China IVD Market Segments

- 3.1 Companion Diagnostics
- 3.1.1 Development Status
- 3.1.2 Market Structure
- 3.1.3 Market Size
- 3.1.4 Growth Drivers
- 3.1.5 Competitive Pattern
- 3.2 Immunological Diagnostics

- 3.2.1 Development Status
- 3.2.2 Competitive Pattern
- 3.2.3 Development Trends
- 3.3 Molecular Diagnostics
- 3.3.1 Development Status
- 3.3.2 Competitive Pattern
- 3.3.3 Development Trends
- 3.4 Biochemical Diagnostics
- 3.4.1 Development Status
- 3.4.2 Competitive Pattern
- 3.4.3 Development Trends
- 3.5 POCT
- 3.5.1 Development Status
- 3.5.2 Competitive Pattern
- 3.5.3 Development Trends

4 China IVD Downstream Sectors

- 4.1 Healthcare Sector
- 4.1.1 Number of Medical Institutions
- 4.1.2 Medical Services
- 4.1.3 Medical Income
- 4.2 Independent Clinical Laboratory Sector
- 4.2.1 Development Status
- 4.2.2 Market Size
- 4.2.3 Competitive Pattern
- 4.2.4 Development Trends

esearch nu hina

The Vertical Portal for China Business Intelligence

Table of contents

5 Major Foreign Companies	5.6.2 Operation
5.1 Roche	5.6.3 In Vitro Diagnostics Business
5.1.1 Profile	5.6.4 Development in China
5.1.2 Operation	
5.1.3 In Vitro Diagnostics Business	6 Major Chinese Companies
5.1.4 Development in China	6.1 Shenzhen Mindray Bio-Medical I
5.2 Siemens	6.1.1 Profile
5.2.1 Profile	6.1.2 Operation
5.2.2 Operation	6.1.3 Gross Margin
5.2.3 In Vitro Diagnostics Business	6.1.4 In Vitro Diagnostics Business
5.2.4 Development in China	6.1.5 Development Strategy
5.3 Abbott	6.2 Autobio Diagnostics Co., Ltd.
5.3.1 Profile	6.2.1 Profile
5.3.2 Operation	6.2.2 Operation
5.3.3 In Vitro Diagnostics Business	6.2.3 Gross Margin
5.3.4 Development in China	6.2.4 In Vitro Diagnostics Business
5.4 Thermo Fisher	6.2.5 Development Strategy
5.4.1 Profile	6.3 Beijing Strong Biotechnologies, I
5.4.2 Operation	6.3.1 Profile
5.4.3 In Vitro Diagnostics Business	6.3.2 Operation
5.4.4 Development in China	6.3.3 Gross Margin
5.5 Danaher	6.3.4 In Vitro Diagnostics Business
5.5.1 Profile	6.3.5 Development Strategy
5.5.2 Operation	6.4 MedicalSystem Biotechnology C
5.5.3 In Vitro Diagnostics Business	6.4.1 Profile
5.5.4 Development in China	6.4.2 Operation
5.6 Sysmex	6.4.3 Gross Margin
5.6.1 Profile	6.4.4 In Vitro Diagnostics Business

Chinese Companies nzhen Mindray Bio-Medical Electronics Co., Ltd. ofile peration oss Margin Vitro Diagnostics Business evelopment Strategy bio Diagnostics Co., Ltd. ofile peration oss Margin Vitro Diagnostics Business evelopment Strategy ng Strong Biotechnologies, Inc. ofile peration oss Margin Vitro Diagnostics Business evelopment Strategy icalSystem Biotechnology Co., Ltd. ofile eration oss Margin Vitro Diagnostics Business

The Vertical Portal for China Business Intelligence

Table of contents

6.4.5 Development Strategy	6.9.3 Gross Margin
6.5 DAAN Gene Co., Ltd. of Sun Yat-sen University	6.9.4 In Vitro Diagnostics Business
6.5.1 Profile	6.9.5 Development Strategy
6.5.2 Operation	6.10 Livzon Pharmaceutical Group Inc.
6.5.3 Gross Margin	6.10.1 Profile
6.5.4 In Vitro Diagnostics Business	6.10.2 Operation
6.5.5 Development Strategy	6.10.3 Gross Margin
6.6 Beijing Leadman Biochemistry Co., Ltd.	6.10.4 In Vitro Diagnostics Business
6.6.1 Profile	6.10.5 Development Strategy
6.6.2 Operation	6.11 Maccura Biotechnology Co., Ltd.
6.6.3 Gross Margin	6.11.1 Profile
6.6.4 In Vitro Diagnostics Business	6.11.2 Operation
6.6.5 Development Strategy	6.11.3 Gross Margin
6.7 Sinocare Inc.	6.11.4 In Vitro Diagnostics Business
6.7.1 Profile	6.11.5 Development Strategy
6.7.2 Operation	6.12 Guangzhou Wondfo Biotech Co., Ltd.
6.7.3 Gross Margin	6.12.1 Profile
6.7.4 In Vitro Diagnostics Business	6.12.2 Operation
6.7.5 Development Strategy	6.12.3 Gross Margin
6.8 Shanghai Kehua Bio-Engineering Co., Ltd.	6.12.4 In Vitro Diagnostics Business
6.8.1 Profile	6.12.5 Development Strategy
6.8.2 Operation	6.13 Biosino Bio-Technology and Science Inc.
6.8.3 Gross Margin	6.13.1 Profile
6.8.4 In Vitro Diagnostics Business	6.13.2 Operation
6.8.5 Development Strategy	6.13.3 Gross Margin
6.9 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	6.13.4 In Vitro Diagnostics Business
6.9.1 Profile	6.13.5 Development Strategy
6.9.2 Operation	6.14 Jiangsu Bioperfectus Technologies Co., Ltd.

The Vertical Portal for China Business Intelligence

Table of contents

6 14 1 Drofile	
6.14.1 Profile	6.18.5 Development Strategy
6.14.2 Operation	6.19 Dirui Industrial Co., Ltd.
6.14.3 Gross Margin	6.19.1 Profile
6.14.4 In Vitro Diagnostics Business	6.19.2 Operation
6.14.5 Development Strategy	6.19.3 Gross Margin
6.15 Zhejiang Orient Gene Biotech Co., Ltd.	6.19.4 In Vitro Diagnostics Business
6.15.1 Profile	6.19.5 Development Strategy
6.15.2 Operation	6.20 Getein Biotech, Inc.
6.15.3 Gross Margin	6.21 Guangdong Hybribio Biotech Co., Ltd.
6.15.4 In Vitro Diagnostics Business	6.22 Beijing Bohui Innovation Biotechnology Co., Ltd.
6.15.5 Development Strategy	6.22.1 Profile
6.16 HOB Biotech Group Suzhou Co., Ltd.	6.22.2 Operation
6.16.1 Profile	6.22.3 Gross Margin
6.16.2 Operation	6.22.4 In Vitro Diagnostics Business
6.16.3 Gross Margin	6.22.5 Development Strategy
6.16.4 In Vitro Diagnostics Business	6.23 Edan Instruments, Inc.
6.16.5 Development Strategy	6.23.1 Profile
6.17 Lifotronic Technology Co., Ltd.	6.23.2 Operation
6.17.1 Profile	6.23.3 Gross Margin
6.17.2 Operation	6.23.4 In Vitro Diagnostics Business
6.17.3 Gross Margin	6.23.5 Development Strategy
6.17.4 In Vitro Diagnostics Business	6.24 Wuhan Easy Diagnosis Biomedicine Co., Ltd.
6.17.5 Development Strategy	6.24.1 Profile
6.18 Hotgen Biotech Co., Ltd.	6.24.2 Operation
6.18.1 Profile	6.24.3 Gross Margin
6.18.2 Operation	6.24.4 In Vitro Diagnostics Business
6.18.3 Gross Margin	6.24.5 Development Strategy
6.18.4 In Vitro Diagnostics Business	o.z. no bovolopinent otratogy

The Vertical Portal for China Business Intelligence

Table of contents

Classification of In Vitro Diagnosis Classification of In Vitro Diagnostic Instruments Classification of In Vitro Diagnostic Reagents Global In Vitro Diagnostic Market Size, 2015-2018 Medical Instrument Market Size in China. 2013-2018 Development History of In Vitro Diagnostic Industry in China In Vitro Diagnostic Market Size in China, 2009-2018 In Vitro Diagnostic Market Size in China, 2018-2025E In Vitro Diagnostic Market Structure in China (by Type), 2018 In Vitro Diagnostic Market Structure in China (by Product), 2018 Competition Pattern of Diagnostic Reagent Industry in China In Vitro Diagnostic Product Layout of Chinese In Vitro Diagnostic Companies IVD Revenue of Major Diagnostic Reagent Enterprises in China, 2014-2018 IVD Market Share of Major Diagnostic Reagent Enterprises in China, 2014-2018 Population Aged over 60 in China, 2009-2018 Total Health Expenditure in China, 2010-2018 Policies on In Vitro Diagnostic Industry in China, 2012-2018 Development Prospects of In Vitro Diagnostic Market Segments in China **Development History of Companion Diagnostic Reagent Kits** Joint Launch History of Targeted Drugs and their Companion Diagnostic Companion Diagnostic Reagents Approved by FDA for Marketing Number of Companion Diagnostic Products Approved in the US (by Technology) Market Share of Companion Diagnostic Reagents in the US (by Technology), 2018 Number of Companion Diagnostic Products Approved in the US (by Target) Number of Companion Diagnostic Products Approved in the US (by Indication) Market Share of Companion Diagnostic Reagents in the US (by Indication), 2018 Global Companion Diagnostic Market Size, 2016-2025E Companion Diagnostic Market Size in China, 2016-2025E

The Vertical Portal for China Business Intelligence

Table of contents

FDA's Regulatory History of Companion Diagnostic Reagents Companion Diagnostic Coverage of Major Insurance Companies in the US Merits and Demerits of Different Companion Diagnostic Business Models Comparison between Five Immunodiagnostic Technologies Chemiluminescence Diagnostic Market Share in China, 2018 Chemiluminescence Diagnosis VS Enzyme-linked Immunodiagnosis Comparison between Main Technologies Applied to Molecular Diagnostics Market Share of Molecular Diagnostic Enterprises in China, 2018 NGS-based Tumor Diagnostic Reagent Kits of Local Chinese Enterprises in Special Approval Procedures for Innovative Medical Instruments Financing Cases in China's Gene Sequencing Industry, 2017-2018 Categories of Biochemical Diagnostic Reagents Categories of Biochemical Diagnostic Systems in China Market Share of Biochemical Diagnostic Enterprises in China, 2018 Applied Scenarios and Fields of POCT Products Comparison between POCT and Clinical Laboratory Diagnosis Market Share of POCT Enterprises in China, 2018 Layout of Chinese Enterprises in POCT Potential POCT Market Size in China Number of Medical and Health Institutions in China, 2015-2019 Number of Hospitals in China, 2009-2019 Number of Hospitals in China by Economic Type, 2009-2019 Clinic Visits of Medical Institutions in China, 2015-2019 Clinic Visits of Hospitals in China, 2009-2019 Clinic Visits of Hospitals in China by Economic Type, 2012-2019 Total Revenue of Medical and Health Institutions in China, 2010-2018 Total Revenue of Medical and Health Institutions in China, 2018-2025E Total Revenue of Hospitals in China, 2009-2018 Comparison of Independent Clinical Laboratory Market Penetration between China, Europe, America and Japan, 2018

The Vertical Portal for China Business Intelligence

Comparison of Diagnostic Item Quantity among Various Medical Institutions Independent Clinical Laboratory Market Size in China, 2010-2018 Number of Independent Clinical Laboratories in China, 2007-2018 Independent Clinical Laboratory Revenue of Main Independent Clinical Laboratory Enterprises in China, 2014-2018 Marker Share of Independent Clinical Laboratory Enterprises in China, 2018 Comprehensive Comparison between Leading Independent Clinical Laboratory Enterprises in China, 2018 Independent Clinical Laboratory Market Size and YoY Growth in China, 2018-2025E Policies on Public Hospital Reform in China, 2015-2019 Number of Private Hospitals and YoY Growth in China, 2009-2018 Clinic Visits of Private Hospitals in China, 2012-2018 Population Aged over 60 in China, 2009-2018 Market Share of Kingmed Diagnostics, 2014-2018 Revenue and Net Income of Roche, 2013-2018 Revenue Structure of Roche by Product, 2013-2018 IVD Revenue of Roche, 2013-2018 Revenue and Net Income of Siemens, 2013-2018 Revenue Structure of Siemens by Product, 2013-2018 IVD Revenue of Siemens, 2013-2018 Revenue and Net Income of Abbott. 2013-2018 Revenue Structure of Abbott by Product, 2013-2018 IVD Revenue of Abbott. 2013-2018 Revenue and Net Income of Thermo Fisher, 2013-2018 Revenue Structure of Thermo Fisher by Product, 2013-2018 IVD Revenue of Thermo Fisher. 2013-2018 Revenue and Net Income of Danaher, 2013-2018 Revenue Structure of Danaher by Product, 2013-2018 IVD Revenue of Danaher, 2013-2018 Revenue and Net Income of Sysmex, 2013-2018

Room 801, B1, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Table of contents

The Vertical Portal for China Business Intelligence

Revenue Structure of Sysmex by Product, 2013-2018 IVD Revenue of Sysmex, 2013-2018 Revenue and Net Income of Shenzhen Mindray Bio-Medical Electronics, 2013-2018 Revenue Structure of Shenzhen Mindray Bio-Medical Electronics by Product, 2013-2018 Gross Margin of Shenzhen Mindray Bio-Medical Electronics, 2013-2018 IVD Revenue of Shenzhen Mindray Bio-Medical Electronics, 2013-2018 Revenue and Net Income of Autobio Diagnostics, 2013-2018 Revenue Structure of Autobio Diagnostics by Product, 2013-2018 Gross Margin of Autobio Diagnostics, 2013-2018 IVD Revenue of Autobio Diagnostics, 2013-2018 Revenue and Net Income of Beijing Strong Biotechnologies, 2013-2018 Revenue Structure of Beijing Strong Biotechnologies by Product, 2013-2018 Gross Margin of Beijing Strong Biotechnologies, 2013-2018 IVD Revenue of Beijing Strong Biotechnologies, 2013-2018 Revenue and Net Income of MedicalSystem Biotechnology, 2013-2018 Revenue Structure of MedicalSystem Biotechnology by Product, 2013-2018 Gross Margin of MedicalSystem Biotechnology, 2013-2018 IVD Revenue of MedicalSystem Biotechnology, 2013-2018 Revenue and Net Income of DAAN Gene, 2013-2018 Revenue Structure of DAAN Gene by Product, 2013-2018 Gross Margin of DAAN Gene, 2013-2018 IVD Revenue of DAAN Gene, 2013-2018 Revenue and Net Income of Beijing Leadman Biochemistry, 2013-2018 Revenue Structure of Beijing Leadman Biochemistry by Product, 2013-2018 Gross Margin of Beijing Leadman Biochemistry, 2013-2018 IVD Revenue of Beijing Leadman Biochemistry, 2013-2018 Revenue and Net Income of Sinocare, 2013-2018 Revenue Structure of Sinocare by Product, 2013-2018

Room 801, B1, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Table of contents

The Vertical Portal for China Business Intelligence

Table of contents

Gross Margin of Sinocare, 2013-2018 IVD Revenue of Sinocare, 2013-2018 Revenue and Net Income of Shanghai Kehua Bio-Engineering, 2013-2018 Revenue Structure of Shanghai Kehua Bio-Engineering by Product, 2013-2018 Gross Margin of Shanghai Kehua Bio-Engineering, 2013-2018 IVD Revenue of Shanghai Kehua Bio-Engineering, 2013-2018 Revenue and Net Income of Shanghai Fosun Pharmaceutical, 2013-2018 Revenue Structure of Shanghai Fosun Pharmaceutical by Product, 2013-2018 Gross Margin of Shanghai Fosun Pharmaceutical, 2013-2018 IVD Revenue of Shanghai Fosun Pharmaceutical, 2013-2018 Revenue and Net Income of Livzon Pharmaceutical Group, 2013-2018 Revenue Structure of Livzon Pharmaceutical Group by Product, 2013-2018 Gross Margin of Livzon Pharmaceutical Group, 2013-2018 IVD Revenue of Livzon Pharmaceutical Group, 2013-2018 Revenue and Net Income of Maccura Biotechnology, 2013-2018 Revenue Structure of Maccura Biotechnology by Product, 2013-2018 Gross Margin of Maccura Biotechnology, 2013-2018 IVD Revenue of Maccura Biotechnology, 2013-2018 Revenue and Net Income of Guangzhou Wondfo Biotech, 2013-2018 Revenue Structure of Guangzhou Wondfo Biotech by Product, 2013-2018 Gross Margin of Guangzhou Wondfo Biotech, 2013-2018 IVD Revenue of Guangzhou Wondfo Biotech, 2013-2018 Revenue and Net Income of Biosino Bio-Technology and Science, 2013-2018 Revenue Structure of Biosino Bio-Technology and Science by Product, 2013-2018 Gross Margin of Biosino Bio-Technology and Science, 2013-2018 IVD Revenue of Biosino Bio-Technology and Science, 2013-2018 Revenue and Net Income of Jiangsu Bioperfectus Technologies, 2013-2018 Revenue Structure of Jiangsu Bioperfectus Technologies by Product, 2013-2018

The Vertical Portal for China Business Intelligence

Table of contents

Gross Margin of Jiangsu Bioperfectus Technologies, 2013-2018 IVD Revenue of Jiangsu Bioperfectus Technologies, 2013-2018 Revenue and Net Income of Zhejiang Orient Gene Biotech, 2013-2018 Revenue Structure of Zhejiang Orient Gene Biotech by Product, 2013-2018 Gross Margin of Zhejiang Orient Gene Biotech, 2013-2018 IVD Revenue of Zhejiang Orient Gene Biotech, 2013-2018 Revenue and Net Income of HOB Biotech Group Suzhou, 2013-2018 Revenue Structure of HOB Biotech Group Suzhou by Product, 2013-2018 Gross Margin of HOB Biotech Group Suzhou, 2013-2018 IVD Revenue of HOB Biotech Group Suzhou, 2013-2018 Revenue and Net Income of Lifotronic Technology, 2013-2018 Revenue Structure of Lifotronic Technology by Product, 2013-2018 Gross Margin of Lifotronic Technology, 2013-2018 IVD Revenue of Lifotronic Technology, 2013-2018 Revenue and Net Income of Hotgen Biotech, 2013-2018 Revenue Structure of Hotgen Biotech by Product, 2013-2018 Gross Margin of Hotgen Biotech, 2013-2018 IVD Revenue of Hotgen Biotech, 2013-2018 Revenue and Net Income of Dirui Industrial, 2013-2018 Revenue Structure of Dirui Industrial by Product, 2013-2018 Gross Margin of Dirui Industrial, 2013-2018 IVD Revenue of Dirui Industrial, 2013-2018 Revenue and Net Income of Getein Biotech, 2013-2018 Revenue Structure of Getein Biotech by Product, 2013-2018 Gross Margin of Getein Biotech, 2013-2018 IVD Revenue of Getein Biotech, 2013-2018 Revenue and Net Income of Guangdong Hybribio Biotech, 2013-2018 Revenue Structure of Guangdong Hybribio Biotech by Product, 2013-2018

The Vertical Portal for China Business Intelligence

Table of contents

Gross Margin of Guangdong Hybribio Biotech, 2013-2018 IVD Revenue of Guangdong Hybribio Biotech, 2013-2018 Revenue and Net Income of Beijing Bohui Innovation Biotechnology, 2013-2018 Revenue Structure of Beijing Bohui Innovation Biotechnology, 2013-2018 Gross Margin of Beijing Bohui Innovation Biotechnology, 2013-2018 IVD Revenue of Beijing Bohui Innovation Biotechnology, 2013-2018 Revenue and Net Income of Edan Instruments, 2013-2018 Revenue Structure of Edan Instruments by Product, 2013-2018 Gross Margin of Edan Instruments, 2013-2018 IVD Revenue of Edan Instruments, 2013-2018 IVD Revenue of Edan Instruments, 2013-2018 Revenue and Net Income of Wuhan Easy Diagnosis Biomedicine, 2013-2018 Revenue Structure of Wuhan Easy Diagnosis Biomedicine by Product, 2013-2018 Gross Margin of Wuhan Easy Diagnosis Biomedicine, 2013-2018 IVD Revenue of Wuhan Easy Diagnosis Biomedicine, 2013-2018 IVD Revenue of Wuhan Easy Diagnosis Biomedicine, 2013-2018

The Vertical Portal for China Business Intelligence

How to Buy

You can place your order in the following alternative ways:

- 1.Order online at www.researchinchina.com
- 2.Fax order sheet to us at fax number:+86 10 82601570
- 3. Email your order to: report@researchinchina.com
- 4. Phone us at +86 10 82600828

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 801, B1, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title Format Cost Total Image: Cost Image: Cost

Choose type of format

PDF (Single user license)	.3,200	USD
Hard copy	3,400	USD
PDF (Enterprisewide license)	4,800	USD

 ※ Reports will be dispatched immediately once full payment has been received.
 Payment may be made by wire transfer or

credit card via PayPal.



The Vertical Portal for China Business Intelligence

RICDB service

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- □ Multi-users market reports
- Database-RICDB
- Custom Research
- Company Search

RICDB (<u>http://www.researchinchina.com/data/database.html</u>), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: